



May 7, 2015

Genomic Health to Present Multiple Oncotype DX® Studies and Positive Liquid Biopsy Results at American Urological Association Annual Meeting May 15-19

New Results Demonstrate Unique Clinical and Health-economic Value of the Oncotype DX Prostate Cancer Test

Positive Liquid Biopsy Results Demonstrate Progress in Development of Bladder Cancer Test

REDWOOD CITY, Calif., May 7, 2015 /PRNewswire/ -- Genomic Health, Inc. (Nasdaq: GHDX) today announced that results from five studies will be presented at the American Urological Association Annual Meeting, which will take place May 15-19 at the New Orleans Ernest N. Morial Convention Center. Poster discussions will include studies supporting wider adoption and reimbursement of the Oncotype DX® prostate cancer test and positive results from an expanded feasibility study in bladder cancer, demonstrating the company's progress in developing a urine-based liquid biopsy test to monitor cancer recurrence.

"These scientific presentations reflect our successful efforts to build the clinical evidence supporting widespread adoption and reimbursement of our prostate cancer test and begin to describe our new platform of non-invasive tests aimed at individualizing cancer care throughout a patient's journey," said Phil Febbo, M.D., chief medical officer, Genomic Health.

Results of the studies will be presented as follows (all times are Central Daylight Time) and abstracts are now available at <http://www.aua2015.org/abstracts>:

Friday, May 15

- **Title:** "The 17-gene Genomic Prostate Score (GPS) Assay: Initial Clinical Experience of 4,000 Patients" (Abstract: MP1-01)
Authors: Katz A, Ho A, Burke E, Denes B, Lu R, Rothney M, Bonham M, Tsiatis A, Lawrence J, Febbo P.
Location: NOMCC 220-221
Time: 10:30 a.m. - 12:30 p.m.
- **Title:** "A Multi-center Comparison of a 17-gene Genomic Prostate Score (GPS) as a Predictor of Outcomes in African-American (AA) and Caucasian (CA) Men with Clinically Localized Prostate Cancer (PCa)" (Abstract: MP1-05)
Authors: Cullen J, Sesterhenn I, Klein E, Mohler J, Carroll P, Cooperberg M, Zhang N, Maddala T, Knezevic D, Tsiatis A, Lawrence HJ, Febbo P.
Location: NOMCC 220-221
Time: 10:30 a.m. - 12:30 p.m.
- **Title:** "Clinical Benefits and Costs of a 17-gene Assay Designed to Assess Disease-Progression Risk after Positive Prostate Cancer Biopsy" (Abstract: MP1-06)
Authors: Dall'Era M, Michalopoulos SN, Denes BS, Tighe J, Hornberger J.
Location: NOMCC 220-221
Time: 10:30 a.m. - 12:30 p.m.

Sunday, May 17

- **Title:** "Comparison of Different Analytical Platforms for the Identification of Tumor DNA in the Urine of Bladder Cancer Patients" (Abstract: MP45-14)
Authors: Resnick MJ, Abramson RD, Yoshizawa C, Lam PN, Shore N, Tezcan H.
Location: NOMCC 243-245
Time: 10:30 a.m. - 12:30 p.m.
- **Title:** "Association Between a 17-gene Genomic Prostate Score and Multi-Parametric Prostate MRI in Men with Low and Intermediate Risk Prostate Cancer (PCa)" (Abstract: MP53-18)
Authors: Leapman M, Westphalen A, Ameli N, Lawrence J, Febbo P, Cooperberg M, Carroll P.
Location: NOMCC 211-213
Time: 1 - 3 p.m.

About Oncotype DX

The Oncotype DX® portfolio of breast, colon and prostate cancer tests applies advanced genomic science to reveal the unique biology of a tumor in order to optimize cancer treatment decisions. The Oncotype DX prostate cancer test identifies low- to intermediate-risk patients eligible for [active surveillance](#), as well as those who may benefit from immediate invasive treatment by predicting disease aggressiveness. With half a million patients tested in more than 80 countries, Oncotype DX testing has redefined personalized medicine by making genomics a critical part of cancer diagnosis and treatment. To learn more about the Oncotype DX prostate cancer test, visit: www.OncotypeDX.com or www.myprostatecancertreatment.org.

About Genomic Health

[Genomic Health](#), Inc. (NASDAQ: GHDX) is the world's leading provider of genomic-based diagnostic tests that address both the overtreatment and optimal treatment of early-stage cancer, one of the greatest issues in healthcare today. The company is applying its world-class scientific and commercial expertise and infrastructure to lead the translation of massive amounts of genomic data into clinically-actionable results for treatment planning throughout the cancer patient's journey, from diagnosis to treatment selection and monitoring. The company is based in [Redwood City](#), California, with European headquarters in Geneva, Switzerland. For more information, please visit, www.GenomicHealth.com and follow the company on Twitter: [@GenomicHealth](#), [Facebook](#), [YouTube](#) and [LinkedIn](#).

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, including statements relating to the belief that the presentations reflect the company's successful efforts to build clinical evidence supporting adoption and reimbursement, and the benefits and attributes of the company's tests or tests in development. Forward-looking statements are subject to risks and uncertainties that could cause actual results to differ materially, and reported results should not be considered as an indication of future performance. These risks and uncertainties include, but are not limited to: the risks and uncertainties associated with the regulation of the company's tests; the results of clinical studies; the applicability of clinical study results to actual outcomes; our ability to develop and commercialize new tests and expand into new markets domestically and internationally; the risk that the company may not obtain or maintain sufficient levels of reimbursement, domestically or abroad, for its existing tests and any future tests it may develop; the risks of competition; unanticipated costs or delays in research and development efforts; the company's ability to obtain capital when needed and the other risks set forth in the company's filings with the Securities and Exchange Commission, including the risks set forth in the company's annual report on Form 10-K for the year ended December 31, 2014. These forward-looking statements speak only as of the date hereof. Genomic Health disclaims any obligation to update these forward-looking statements.

NOTE: The Genomic Health logo, Oncotype, Oncotype DX, Recurrence Score, and DCIS Score are trademarks or registered trademarks of Genomic Health, Inc. All other trademarks and service marks are the property of their respective owners.



Logo - <http://photos.prnewswire.com/prnh/20130425/SF01493LOGO>

To view the original version on PR Newswire, visit: <http://www.prnewswire.com/news-releases/genomic-health-to-present-multiple-ncotype-dx-studies-and-positive-liquid-biopsy-results-at-american-urological-association-annual-meeting-may-15-19-300078775.html>

SOURCE Genomic Health, Inc.

News Provided by Acquire Media